Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Hepatitis Drugs Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 VEMLIDY
  • 1.3.3 EPCLUSA
  • 1.3.4 SOVALDI
  • 1.3.5 INCIVEK
  • 1.3.6 OLYSIO
  • 1.3.7 VICTRELIS
  • 1.3.8 VIREAD
  • 1.3.9 HEPSERA
  • 1.3.10 BARACLUDE
  • 1.3.11 TYZEKA
• 1.4 Market Segment by Application
  • 1.4.1 Global Hepatitis Drugs Market Share by Application (2019-2025)
  • 1.4.2 Hepatitis A
  • 1.4.3 Hepatitis B
  • 1.4.4 Hepatitis C
  • 1.4.5 Hepatitis D
  • 1.4.6 Hepatitis E
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Hepatitis Drugs Market Size
  • 2.1.1 Global Hepatitis Drugs Revenue 2014-2025
  • 2.1.2 Global Hepatitis Drugs Sales 2014-2025
• 2.2 Hepatitis Drugs Growth Rate by Regions
  • 2.2.1 Global Hepatitis Drugs Sales by Regions 2014-2019
  • 2.2.2 Global Hepatitis Drugs Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Hepatitis Drugs Sales by Manufacturers
  • 3.1.1 Hepatitis Drugs Sales by Manufacturers 2014-2019
  • 3.1.2 Hepatitis Drugs Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Hepatitis Drugs Revenue by Manufacturers (2014-2019)
  • 3.2.2 Hepatitis Drugs Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Hepatitis Drugs Market Concentration Ratio (CR5 and HHI)
• 3.3 Hepatitis Drugs Price by Manufacturers
• 3.4 Key Manufacturers Hepatitis Drugs Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Hepatitis Drugs Market
• 3.6 Key Manufacturers Hepatitis Drugs Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 VEMLIDY Sales and Revenue (2014-2019)
  • 4.1.2 EPCLUSA Sales and Revenue (2014-2019)
  • 4.1.3 SOVALDI Sales and Revenue (2014-2019)
  • 4.1.4 INCIVEK Sales and Revenue (2014-2019)
  • 4.1.5 OLYSIO Sales and Revenue (2014-2019)
  • 4.1.6 VICTRELIS Sales and Revenue (2014-2019)
  • 4.1.7 VIREAD Sales and Revenue (2014-2019)
  • 4.1.8 HEPSERA Sales and Revenue (2014-2019)
  • 4.1.9 BARACLUDE Sales and Revenue (2014-2019)
  • 4.1.10 TYZEKA Sales and Revenue (2014-2019)
• 4.2 Global Hepatitis Drugs Sales Market Share by Type
• 4.3 Global Hepatitis Drugs Revenue Market Share by Type
• 4.4 Hepatitis Drugs Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Hepatitis Drugs Sales by Application

6 United States

• 6.1 United States Hepatitis Drugs Breakdown Data by Company
• 6.2 United States Hepatitis Drugs Breakdown Data by Type
• 6.3 United States Hepatitis Drugs Breakdown Data by Application

7 European Union

• 7.1 European Union Hepatitis Drugs Breakdown Data by Company
• 7.2 European Union Hepatitis Drugs Breakdown Data by Type
• 7.3 European Union Hepatitis Drugs Breakdown Data by Application

8 China

• 8.1 China Hepatitis Drugs Breakdown Data by Company
• 8.2 China Hepatitis Drugs Breakdown Data by Type
• 8.3 China Hepatitis Drugs Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Hepatitis Drugs Breakdown Data by Company
• 9.2 Rest of World Hepatitis Drugs Breakdown Data by Type
• 9.3 Rest of World Hepatitis Drugs Breakdown Data by Application
• 9.4 Rest of World Hepatitis Drugs Breakdown Data by Countries
  • 9.4.1 Rest of World Hepatitis Drugs Sales by Countries
  • 9.4.2 Rest of World Hepatitis Drugs Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 F. Hoffmann-La Roche
  • 10.1.1 F. Hoffmann-La Roche Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Hepatitis Drugs
  • 10.1.4 Hepatitis Drugs Product Introduction
  • 10.1.5 F. Hoffmann-La Roche Recent Development
• 10.2 Gilead Sciences
  • 10.2.1 Gilead Sciences Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Hepatitis Drugs
  • 10.2.4 Hepatitis Drugs Product Introduction
  • 10.2.5 Gilead Sciences Recent Development
• 10.3 GlaxoSmithKline
  • 10.3.1 GlaxoSmithKline Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Hepatitis Drugs
  • 10.3.4 Hepatitis Drugs Product Introduction
  • 10.3.5 GlaxoSmithKline Recent Development
• 10.4 Johnson & Johnson
  • 10.4.1 Johnson & Johnson Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Hepatitis Drugs
  • 10.4.4 Hepatitis Drugs Product Introduction
  • 10.4.5 Johnson & Johnson Recent Development
• 10.5 Merck
  • 10.5.1 Merck Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Hepatitis Drugs
  • 10.5.4 Hepatitis Drugs Product Introduction
  • 10.5.5 Merck Recent Development
• 10.6 Novartis
  • 10.6.1 Novartis Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Hepatitis Drugs
  • 10.6.4 Hepatitis Drugs Product Introduction
  • 10.6.5 Novartis Recent Development
• 10.7 Vertex Pharmaceuticals
  • 10.7.1 Vertex Pharmaceuticals Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Hepatitis Drugs
  • 10.7.4 Hepatitis Drugs Product Introduction
  • 10.7.5 Vertex Pharmaceuticals Recent Development
• 10.8 Abbvie
  • 10.8.1 Abbvie Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Hepatitis Drugs
  • 10.8.4 Hepatitis Drugs Product Introduction
  • 10.8.5 Abbvie Recent Development
• 10.9 Achillion Pharmaceuticals
  • 10.9.1 Achillion Pharmaceuticals Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Hepatitis Drugs
  • 10.9.4 Hepatitis Drugs Product Introduction
  • 10.9.5 Achillion Pharmaceuticals Recent Development
• 10.10 Bristol-Myers Squibb
  • 10.10.1 Bristol-Myers Squibb Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Hepatitis Drugs
  • 10.10.4 Hepatitis Drugs Product Introduction
  • 10.10.5 Bristol-Myers Squibb Recent Development

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Hepatitis Drugs Sales Channels
  • 11.2.2 Hepatitis Drugs Distributors
• 11.3 Hepatitis Drugs Customers

12 Market Forecast

• 12.1 Global Hepatitis Drugs Sales and Revenue Forecast 2019-2025
• 12.2 Global Hepatitis Drugs Sales Forecast by Type
• 12.3 Global Hepatitis Drugs Sales Forecast by Application
• 12.4 Hepatitis Drugs Forecast by Regions
  • 12.4.1 Global Hepatitis Drugs Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Hepatitis Drugs Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases. The viruses that cause hepatitis are of several types: A, B, C, D, E, and G. The most common type of hepatitis viruses are A, B, and C. Hepatitis viruses can cause either acute or chronic infections.
Factors such as growth in injection drug users, increase in awareness, presence of unmet need, and anticipated launch of new drugs are expected to drive the market growth during the forecast period. The market is witnessing the emerging trend of pediatric combination vaccines, which protect against multiple causative agents and thereby reduce the costs gain in packaging and administering individual vaccines. The markets in India, Brazil, China, and Russia are also expected to grow at a rapid pace during the forecast period as the prevalence of hepatitis in these countries is high.
The major drivers of the hepatitis drugs market include the second generation DAAs of Olysio and Sovaldi. Second generation DAAs are more efficacious and have lesser adverse effects. Currently, the market players are developing IFN therapies for the treatment of Hepatitis C. These therapies are intended to be all-oral regimens. The HCV drugs segment comprised more than 84% of the total market share in 2017. A major focus in this segment is expected to drive the growth of the hepatitis drugs market in the future.
In 2019, the market size of Hepatitis Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Hepatitis Drugs.

This report studies the global market size of Hepatitis Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Hepatitis Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
F. Hoffmann-La Roche
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck
Novartis
Vertex Pharmaceuticals
Abbvie
Achillion Pharmaceuticals
Bristol-Myers Squibb

Market Segment by Product Type
VEMLIDY
EPCLUSA
SOVALDI
INCIVEK
OLYSIO
VICTRELIS
VIREAD
HEPSERA
BARACLUDE
TYZEKA

Market Segment by Application
Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D
Hepatitis E

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Hepatitis Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Hepatitis Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Hepatitis Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025